CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exo Therapeutics, Inc., a pre-clinical company developing a pipeline of drug candidates that target exosites, unique small-molecule binding pockets that are distinct ...
Exo Therapeutics, Inc., a pre-clinical company developing a pipeline of drug candidates that target exosites, unique small-molecule binding pockets that are distal to traditional active and allosteric ...
– Efficacy of exosite-targeted TBK1/STING inhibitor validated across multiple preclinical models, supporting nomination of lead development candidate for treatment of autoimmune diseases – CAMBRIDGE, ...
Exo Therapeutics is a small molecule drug discovery and development company co-founded by Professors David R. Liu, Alan Saghatelian, and Juan Pablo Maianti with a pioneering technology to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback